News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Precision Therapeutics, Inc.' ChemoFx® Test Useful in Determining Treatment for Resistant and Recurrent Gynecologic Cancer Patients


9/6/2012 10:01:42 AM

PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics has released the results of a study that determines whether ChemoFx® results change from primary diagnosis to recurrence of disease in gynecological tumors with intervening administration of adjuvant chemotherapy. ChemoFx®is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES